Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.

Hdl Handle:
http://hdl.handle.net/10147/237974
Title:
Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.
Authors:
Frazão, J M; Messa, P; Mellotte, G J; Geiger, H; Hagen, E C; Quarles, L D; Kerr, P G; Baños, A; Dehmel, B; Urena, P
Affiliation:
School of Medicine, Porto University, Porto, Portugal. jmmdfrazao@netcabo.pt
Citation:
Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. 2011, 76 (3):233-43 Clin. Nephrol.
Journal:
Clinical nephrology
Issue Date:
Sep-2011
URI:
http://hdl.handle.net/10147/237974
PubMed ID:
21888861
Abstract:
To evaluate the relationship between the severity of secondary hyperparathyroidism (SHPT) - defined in terms of baseline plasma intact parathyroid hormone (iPTH) level - and the magnitude of response to cinacalcet.
Item Type:
Article
Language:
en
MeSH:
Adult; Aged; Aged, 80 and over; Calcimimetic Agents; Calcium; Female; Humans; Hyperparathyroidism, Secondary; Male; Middle Aged; Naphthalenes; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Young Adult
ISSN:
0301-0430

Full metadata record

DC FieldValue Language
dc.contributor.authorFrazão, J Men_GB
dc.contributor.authorMessa, Pen_GB
dc.contributor.authorMellotte, G Jen_GB
dc.contributor.authorGeiger, Hen_GB
dc.contributor.authorHagen, E Cen_GB
dc.contributor.authorQuarles, L Den_GB
dc.contributor.authorKerr, P Gen_GB
dc.contributor.authorBaños, Aen_GB
dc.contributor.authorDehmel, Ben_GB
dc.contributor.authorUrena, Pen_GB
dc.date.accessioned2012-08-09T13:34:26Z-
dc.date.available2012-08-09T13:34:26Z-
dc.date.issued2011-09-
dc.identifier.citationCinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. 2011, 76 (3):233-43 Clin. Nephrol.en_GB
dc.identifier.issn0301-0430-
dc.identifier.pmid21888861-
dc.identifier.urihttp://hdl.handle.net/10147/237974-
dc.description.abstractTo evaluate the relationship between the severity of secondary hyperparathyroidism (SHPT) - defined in terms of baseline plasma intact parathyroid hormone (iPTH) level - and the magnitude of response to cinacalcet.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Clinical nephrologyen_GB
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshCalcimimetic Agents-
dc.subject.meshCalcium-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshHyperparathyroidism, Secondary-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNaphthalenes-
dc.subject.meshParathyroid Hormone-
dc.subject.meshPhosphates-
dc.subject.meshRandomized Controlled Trials as Topic-
dc.subject.meshYoung Adult-
dc.titleCinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity.en_GB
dc.typeArticleen
dc.contributor.departmentSchool of Medicine, Porto University, Porto, Portugal. jmmdfrazao@netcabo.pten_GB
dc.identifier.journalClinical nephrologyen_GB
dc.description.provinceLeinsteren

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.